Aza/pano treatment reduces ALL cell adhesion and BM load. (A) Peripheral blood analysis of vehicle-treated and aza/pano-treated mice identifying CD10⁺ human leukemic cells (NTPL-87). *P < .05. (B) Mouse femur sections collected at day 8 (following completion of AP treatment; Figure 6A) were stained with hematoxylin and eosin or anti-human mitochondria antibody to detect human cells (brown). Scale bar, 50 μm. (C) Graphical representation and representative plots of CD81 surface expression on human leukemic cells from peripheral blood (PB) and bone marrow (BM) in mice transplanted with WT (n = 2) or CD81KO (n = 4) cells; *P < 005, **P < .01. (D) Following completion of DA treatments (15 days after cell injection; Figure 6A), femur sections were stained with hematoxylin and eosin or anti-human mitochondria antibody. Scale, bar, 50 μm. (E) Following completion of DA treatments (15 days after cell injection; Figure 6A), mouse femur sections were stained with anti-human p53 antibody. Scale bar, 50 μm. Average p53 expression per cell was quantified using the immunohistochemistry toolbox from Image J (n = 60-120). Average values with standard deviation and minimum/maximum are presented in the graph (*P < .001).